DE69028535T2 - Herstellung des vaskulären endothelialen zellwachstumsfaktors - Google Patents

Herstellung des vaskulären endothelialen zellwachstumsfaktors

Info

Publication number
DE69028535T2
DE69028535T2 DE69028535T DE69028535T DE69028535T2 DE 69028535 T2 DE69028535 T2 DE 69028535T2 DE 69028535 T DE69028535 T DE 69028535T DE 69028535 T DE69028535 T DE 69028535T DE 69028535 T2 DE69028535 T2 DE 69028535T2
Authority
DE
Germany
Prior art keywords
growth factor
cell growth
vascular endothelial
endothelial cell
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69028535T
Other languages
English (en)
Other versions
DE69028535D1 (de
Inventor
Edmund Tischer
Judith Abraham
John Fiddes
Richard Mitchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scios LLC
Original Assignee
Scios Nova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Nova Inc filed Critical Scios Nova Inc
Application granted granted Critical
Publication of DE69028535D1 publication Critical patent/DE69028535D1/de
Publication of DE69028535T2 publication Critical patent/DE69028535T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
DE69028535T 1989-07-27 1990-07-27 Herstellung des vaskulären endothelialen zellwachstumsfaktors Expired - Lifetime DE69028535T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38754589A 1989-07-27 1989-07-27
US07/450,883 US5194596A (en) 1989-07-27 1989-12-14 Production of vascular endothelial cell growth factor
PCT/US1990/004227 WO1991002058A1 (en) 1989-07-27 1990-07-27 Production of vascular endothelial cell growth factor

Publications (2)

Publication Number Publication Date
DE69028535D1 DE69028535D1 (de) 1996-10-17
DE69028535T2 true DE69028535T2 (de) 1997-04-10

Family

ID=27011922

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69028535T Expired - Lifetime DE69028535T2 (de) 1989-07-27 1990-07-27 Herstellung des vaskulären endothelialen zellwachstumsfaktors

Country Status (10)

Country Link
US (1) US5194596A (de)
EP (1) EP0484401B1 (de)
JP (4) JP3523645B2 (de)
AT (1) ATE142693T1 (de)
AU (1) AU6079890A (de)
CA (1) CA2063810C (de)
DE (1) DE69028535T2 (de)
DK (1) DK0484401T3 (de)
ES (1) ES2094159T3 (de)
WO (1) WO1991002058A1 (de)

Families Citing this family (434)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048729A (en) * 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
WO1990011084A1 (en) * 1989-03-24 1990-10-04 The Regents Of The University Of California Endothelial cell growth factor, isolation and expression
US6899882B1 (en) 1989-03-24 2005-05-31 The Regents Of The University Of California Endothelial cell growth factor methods of isolation and expression
US7300791B2 (en) * 1989-05-12 2007-11-27 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US20030114374A1 (en) * 1989-05-12 2003-06-19 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
DE69024261T2 (de) * 1989-05-24 1996-07-18 Merck & Co Inc Reinigung und Charakterisierung eines von einem Glioma abstammenden Wachstumsfaktors
US5726152A (en) * 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
EP0506477B1 (de) * 1991-03-28 1999-06-23 Merck & Co. Inc. Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US5514779A (en) * 1991-06-07 1996-05-07 Zeneca Limited Biocidal proteins from plants
AU2861692A (en) * 1991-10-18 1993-05-21 Beth Israel Hospital Association, The Vascular permeability factor targeted compounds
AU674500B2 (en) * 1991-11-04 1997-01-02 Genetics Institute, Llc Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US6054288A (en) * 1991-11-05 2000-04-25 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6692737B1 (en) 1991-11-05 2004-02-17 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
US6531124B1 (en) 1992-07-10 2003-03-11 Transkaryotic Therapies, Inc. In vivo production and delivery of insulinotropin for gene therapy
PT662146E (pt) * 1992-09-03 2000-12-29 Univ California Factor que afecta o tecido dorsal e composicoes
HU225646B1 (en) * 1992-10-28 2007-05-29 Genentech Inc Hvegf receptors as vascular endothelial cell growth factor antagonists
JPH08508511A (ja) * 1993-04-29 1996-09-10 ワシントン・ユニバーシテイー 副行循環の改善への血小板由来成長因子の使用
DK0706563T3 (da) * 1993-06-29 2005-01-31 Chiron Corp Afkortet keratonocyt-vækstfaktor (KGF) med foröget biologisk aktivetet
WO1995006131A1 (en) * 1993-08-23 1995-03-02 Monash University A method for the assay, prophylaxis and/or treatment of human disease conditions
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
CA2179638A1 (en) * 1993-12-24 1995-07-06 Peter Schulz-Knappe Human circulating cytokine cc-1
US5480975A (en) * 1994-02-08 1996-01-02 Brigham And Women's Hospital Induction of vascular endothelial growth factor (VEGF) by transition metals
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
EP0751992B1 (de) * 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vaskularer endothelialer wachstumsfaktor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6150092A (en) * 1994-06-27 2000-11-21 Taogosei Company, Ltd. Antisense nucleic acid compound targeted to VEGF
US6152141A (en) * 1994-07-28 2000-11-28 Heartport, Inc. Method for delivery of therapeutic agents to the heart
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US6451523B1 (en) * 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
IL114615A0 (en) * 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
CA2212573A1 (en) * 1995-02-09 1996-08-15 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Nucleotide and deduced amino acid sequences of tumor gene int6
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) * 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US7160991B1 (en) * 1995-03-02 2007-01-09 Ludwig Institute For Cancer Research Vascular endothelial growth factor polypeptides
CA2214439C (en) * 1995-03-02 2002-12-17 Amrad Operations Pty. Ltd. A novel growth factor and a genetic sequence encoding same
IL117645A (en) * 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
JPH11503012A (ja) * 1995-03-30 1999-03-23 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ヒトｇタンパク質結合レセプター
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7427492B1 (en) * 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US20020150578A1 (en) * 1995-06-05 2002-10-17 Human Genome Sciences, Inc. Human prostatic specific reductase
US20020026037A1 (en) * 1995-06-06 2002-02-28 Jing-Shan Hu Vascular endothelial growth factor 3 antibodies
US6013483A (en) 1995-06-07 2000-01-11 Human Genome Sciences, Inc. DNA encoding endothelial monocyte activating polypeptide III
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
ES2187667T3 (es) * 1995-08-15 2003-06-16 Connetics Corp Uso de relaxina para estimular angiogenesis.
EP1382679A3 (de) * 1995-09-08 2004-11-10 Genentech, Inc. Antagonisten gegen Vaskuläres Endothelzellen Wachstumsfaktor-verwandtes Protein (VRP)
US6329169B1 (en) * 1995-09-29 2001-12-11 Human Genome Sciences, Inc. Nucleic acid molecules encoding cytostatin II
AU7142996A (en) * 1995-09-29 1997-04-28 Universita' Degli Studi Di Siena Regulated genes and uses thereof
BR9611174A (pt) * 1995-10-23 1999-09-14 Childrens Medical Center Proteína de endostatina isolada, e composições terapêuticas antiangiogénicas formadas com a mesma.
US7393943B1 (en) * 1995-12-08 2008-07-01 Human Genome Sciences, Inc. Polynucleotides encoding a human chemotactic cytokine I
US7888466B2 (en) * 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
US7084252B1 (en) * 1996-01-16 2006-08-01 The Rockefeller University DB, the receptor for leptin
ATE364629T1 (de) * 1996-01-22 2007-07-15 Curis Inc Methoden zur herstellung von op-1 morphogen analoge
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
EP0888086B1 (de) 1996-02-15 2005-07-27 Biosense Webster, Inc. Sonde zur exkavation
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) * 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US6410268B1 (en) 1996-03-18 2002-06-25 Human Genome Sciences, Inc. Polynucleotides encoding chemokine alpha-3
US6443974B1 (en) 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
ES2390107T3 (es) * 1996-08-23 2012-11-06 Vegenics Pty Ltd Factor recombinante de crecimiento de las células endoteliales vasculares-D (VEGF-D)
US20030129643A1 (en) * 1996-08-23 2003-07-10 Human Genome Sciences, Inc. T1 receptor-like ligand I
CA2235867A1 (en) * 1996-08-27 1998-03-05 Kyowa Hakko Kogyo Co., Ltd. Hematopoietic stem cell growth factor (scgf)
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
WO1998013071A1 (en) * 1996-09-24 1998-04-02 Merck & Co., Inc. Gene therapy for inhibition of angiogenesis
US20070299005A1 (en) * 1996-09-24 2007-12-27 Tanox, Inc. Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US6998418B1 (en) 1996-11-05 2006-02-14 Gp Medical, Inc. Acellular biological material chemically treated with genipin
US20060171907A1 (en) * 1996-11-21 2006-08-03 The Procter & Gamble Company Oral care compositions providing enhanced whitening and stain prevention
AU713471C (en) * 1996-12-23 2002-04-18 Immunex Corporation Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily
US8003386B1 (en) * 1997-01-14 2011-08-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α and 6β
US20040013664A1 (en) * 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
US7285267B2 (en) * 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US20030165467A1 (en) * 1997-01-21 2003-09-04 Technion Research & Development Co., Ltd. Angiogenic factor and use thereof in treating cardiovascular disease
EP0972022A2 (de) * 1997-01-21 2000-01-19 Human Genome Sciences, Inc. Für rezeptoren kodierende polynukleotide und polypeptide
US20020155538A1 (en) * 1997-01-23 2002-10-24 Incyte Pharmaceuticals, Inc. Novel endothelial growth factor
WO1998033918A1 (en) * 1997-02-05 1998-08-06 The Regents Of The University Of California Morphogenic proteins
US5968780A (en) * 1997-02-06 1999-10-19 Human Genome Sciences, Inc. Dendritic cell-derived growth factor
US6395707B1 (en) * 1997-02-14 2002-05-28 Genentech, Inc. Methods of treatment utilizing variants of vascular endothelial cell growth factor
US6485942B1 (en) 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US6951924B2 (en) * 1997-03-14 2005-10-04 Human Genome Sciences, Inc. Antibodies against secreted protein HTEBYII
US7968689B2 (en) * 1997-03-07 2011-06-28 Human Genome Sciences, Inc. Antibodies to HSDEK49 polypeptides
US7196164B2 (en) * 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
WO2000029422A1 (en) * 1998-11-12 2000-05-25 Human Genome Sciences, Inc. 31 human secreted proteins
WO2000075375A1 (en) * 1999-06-07 2000-12-14 Human Genome Sciences, Inc. 26 human secreted proteins
US20060084082A1 (en) 1997-03-07 2006-04-20 Human Genome Sciences, Inc. 186 human secreted proteins
ATE296117T1 (de) 1997-03-07 2005-06-15 Wistar Inst Verwendung von adenoviralen vektoren, die pdgf oder vegf exprimieren, zur heilung von gewebsdefekten und zur induzierung der hypervaskulität in säugergeweben
US6541212B2 (en) 1997-03-10 2003-04-01 The Regents Of The University Of California Methods for detecting prostate stem cell antigen protein
US5935813A (en) * 1997-03-20 1999-08-10 Incyte Pharmaceuticals, Inc. Human pancreatitis-associated protein
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1005355A4 (de) * 1997-04-15 2002-07-17 Radix Organization Inc Verfahren zur behandlung von magendarmgeschwüren und die dazugehörigen mittel
US7205381B2 (en) * 1997-04-21 2007-04-17 Schering Corporation Mammalian cytokines; related reagents and methods
US20030166065A1 (en) * 1997-04-24 2003-09-04 Human Genome Sciences, Inc. Novel integrin ligand ITGL-TSP
US7220557B2 (en) * 1997-04-24 2007-05-22 Human Genome Sciences, Inc. METH1 polynucleotides
EP0979282A1 (de) * 1997-04-30 2000-02-16 F. Hoffmann-La Roche Ag Rattenchemonikin st38.2
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6506569B1 (en) * 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
US6031155A (en) * 1997-06-05 2000-02-29 Cameron-Mills; Verena Arabinoxylan degradation
US20060223077A1 (en) * 1997-06-06 2006-10-05 Human Genome Sciences, Inc. 207 human secreted proteins
US5891674A (en) * 1997-06-19 1999-04-06 Incyte Pharmaceuticals, Inc. Insulin receptor tyrosine kinase substrate
US6617129B2 (en) * 1997-06-27 2003-09-09 Human Genome Sciences, Inc. Human NK-3 related prostate specific gene-1
WO1999006445A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
WO1999006444A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University Of School Of Medicine GROWTH DIFFERENTIATION FACTOR, Lefty-1
WO1999006443A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor, lefty-2
US6416973B1 (en) * 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
WO1999025825A2 (en) * 1997-11-13 1999-05-27 Genset EXTENDED cDNAs FOR SECRETED PROTEINS
US20020112251A1 (en) * 1997-08-04 2002-08-15 Mccarthy Sean A. Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic and other uses
FR2767135B1 (fr) * 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
US20040213789A1 (en) * 1997-09-02 2004-10-28 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US20030161823A1 (en) * 1998-08-31 2003-08-28 Neta Ilan Therapeutic and cosmetic uses of heparanases
US20020088019A1 (en) * 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
US6699672B1 (en) * 1997-09-02 2004-03-02 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use research and medical applications
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US20030082540A1 (en) * 1997-09-17 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6482923B1 (en) * 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
WO1999014240A1 (en) * 1997-09-17 1999-03-25 Human Genome Sciences, Inc. Interleukin-17 receptor-like protein
KR100613531B1 (ko) * 1997-09-22 2006-08-16 도시오 미야타 멕신 단백질
US7321023B2 (en) * 1997-11-07 2008-01-22 Incyte Corporation SP16 protein
US6392019B1 (en) 1997-11-22 2002-05-21 John Ford Antibodies specific for EGF motif proteins
US6808890B2 (en) * 1999-07-28 2004-10-26 Nuvelo, Inc. Method of detecting a cancerous cell expressing EGFL6, and EGF mutif protein
US20060009633A9 (en) * 1997-11-13 2006-01-12 Genset, S.A. Complementary DNAs encoding proteins with signal peptides
US20060286639A1 (en) * 1997-11-13 2006-12-21 Serono Genetics Institute S.A. Complementary DNAs encoding proteins with signal peptides
WO1999027096A1 (en) 1997-11-22 1999-06-03 Hyseq, Inc. A NOVEL EGF MOTIF PROTEIN OBTAINED FROM A cDNA LIBRARY OF FETAL LIVER-SPLEEN
US20020132981A1 (en) * 1997-12-03 2002-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1037982A1 (de) * 1997-12-08 2000-09-27 Ontogeny, Inc. Menschliche patched gene und proteine, und entsprechende verwendungen
US6303770B1 (en) * 1997-12-10 2001-10-16 Zymogenetics, Inc. Nucleic acids encoding mammalian alpha helical protein-1
CN1283997A (zh) 1997-12-22 2001-02-14 人类基因组科学公司 角质形成细胞生长因子－2制剂
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6703485B2 (en) * 1997-12-23 2004-03-09 The Trustees Of Columbia University In The City Of New York Brain and heart cyclic nucleotide gated ion channel compounds and uses thereof
JP2003517265A (ja) * 1997-12-24 2003-05-27 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 血管内皮増殖因子ｄを発現する発現ベクターおよび細胞系、およびメラノーマを治療する方法
JPH11187884A (ja) * 1997-12-26 1999-07-13 Hsp Kenkyusho:Kk 熱ショック転写因子結合蛋白質
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
EP1044211A4 (de) * 1998-01-07 2005-03-23 Human Genome Sciences Inc 36 menschliche sekretierte proteine
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7722671B1 (en) 1998-01-27 2010-05-25 St. Jude Medical, Inc. Medical devices with associated growth factors
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
DE69838526T2 (de) 1998-02-05 2008-07-03 Biosense Webster, Inc., Diamond Bar Gerät zum Freisetzen eines Medikaments im Herzen
US6479654B1 (en) 1998-02-06 2002-11-12 Collateral Therapeutics Forms of the angiogenic factor vascular endothelial cell growth factor: VEGF
US6706869B1 (en) * 1998-02-11 2004-03-16 Wyeth Map kinase phosphatases and polynucleotides encoding them
US6395890B1 (en) * 1998-02-20 2002-05-28 Zymogenetics, Inc. Nucleic acids encoding connective tissue growth factor homologs
US6054276A (en) 1998-02-23 2000-04-25 Macevicz; Stephen C. DNA restriction site mapping
US7579160B2 (en) * 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US20050026248A1 (en) * 1998-03-26 2005-02-03 Hsueh Aaron J.W. Novel mammalian G-protein coupled receptors having extracellular leucine rich repeat regions
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
US6573095B1 (en) * 1998-04-29 2003-06-03 Genesis Research & Development Corporation Limited Polynucleotides isolated from skin cells
EP1077259A4 (de) * 1998-05-14 2005-04-20 Ono Pharmaceutical Co Neue polypeptide, dafür kodierende cdnas und deren verwendung
US20030134327A1 (en) * 1998-05-15 2003-07-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1082433A4 (de) * 1998-05-29 2003-01-02 Human Genome Sciences Inc Interleukine 21 und 22
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
AU4411499A (en) * 1998-06-05 1999-12-20 Human Genome Sciences, Inc. Connective tissue growth factor-4
US20070020724A1 (en) 1998-06-16 2007-01-25 Ruben Steven M 94 human secreted proteins
BRPI9912819B8 (pt) * 1998-07-14 2021-05-25 Janssen Pharmaceutica Nv vetor de expressão, micro-organismo transgênico, usos de uma molécula de ácido nucléico e de um fator de crescimento neurotrófico, bem como composições farmacêuticas compreendendo os mesmos
US7067473B1 (en) * 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
US20070014787A1 (en) 1998-07-15 2007-01-18 Human Genome Sciences, Inc. 71 human secreted proteins
US20050048612A1 (en) * 1998-07-28 2005-03-03 Incyte Corporation Human epidermal proteins HEP1-1 to HEP1-6
US6706951B1 (en) * 1998-08-17 2004-03-16 Pioneer Hi-Bred International, Inc. Maize nucleic acid encoding a GDP-mannose pyrophosphorylase
AU5551599A (en) * 1998-08-20 2000-03-14 Pioneer Hi-Bred International, Inc. Compositions and methods for altering an acetyl-coa metabolic pathway of a plant
US20030217375A1 (en) * 1998-08-31 2003-11-20 Eyal Zcharia Transgenic animals expressing heparanase and uses thereof
WO2000012707A1 (en) * 1998-09-02 2000-03-09 Millennium Pharmaceuticals, Inc. 14926 receptor, a novel g-protein coupled receptor
IL141687A0 (en) * 1998-09-09 2002-03-10 Scios Inc Treatment of microvascular angiopathies
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
EP1417971A3 (de) * 1998-09-09 2004-06-30 Scios Inc. Verwendung eines angiogenen Faktors zur Behandlung von mikrovaskulären Angiopathien
WO2000015793A2 (en) * 1998-09-17 2000-03-23 Incyte Pharmaceuticals, Inc. Human gpcr proteins
US6680380B1 (en) * 1998-09-18 2004-01-20 Schering Corporation Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods
US20040058355A1 (en) * 1998-09-30 2004-03-25 Millennium Pharmaceuticals, Inc. Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor
WO2000018923A2 (en) * 1998-09-30 2000-04-06 Millennium Pharmaceuticals, Inc. Slgp protein and nucleic acid molecule and uses therefor
AU6411199A (en) * 1998-10-13 2000-05-01 Chiron Corporation Angiogenically effective unit dose of fgf and method of administering
US20030166550A1 (en) * 1999-08-27 2003-09-04 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US6440934B1 (en) 1998-10-13 2002-08-27 Chiron Corporation Angiogenically effective unit dose of FGF-2 and method of use
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US6375680B1 (en) 1998-12-01 2002-04-23 St. Jude Medical, Inc. Substrates for forming synthetic tissues
JP2002532083A (ja) * 1998-12-17 2002-10-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４７個のヒト分泌タンパク質
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
JP2000189171A (ja) * 1998-12-25 2000-07-11 Banyu Pharmaceut Co Ltd 新規なグアノシン三リン酸（ｇｔｐ）結合タンパク質共役型のレセプタ―タンパク質
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000043520A2 (en) * 1999-01-25 2000-07-27 University Of Florida Materials and methods for producing geminivirus resistant plants
JP2002535997A (ja) * 1999-02-02 2002-10-29 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 細胞の老化および細胞の最終分化の際に向上した発現を示す遺伝子、およびその使用
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
CA2361293A1 (en) * 1999-02-10 2000-08-17 Human Genome Sciences, Inc. 33 human secreted proteins
DE19906096A1 (de) * 1999-02-13 2000-08-17 Walter Sebald Protein mit einem Heparin-bindenden Epitop
US6392126B1 (en) * 1999-02-25 2002-05-21 Pioneer Hi-Bred International, Inc. Adenosine deaminase homologues and uses thereof
US6406907B1 (en) * 1999-02-26 2002-06-18 Iowa State University Research Foundation Bovine tumor necrosis factor receptor-1 and methods of use
US7083793B2 (en) * 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
AU2878600A (en) * 1999-03-01 2000-09-21 Hadasit Medical Research Services & Development Company Ltd Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
IL128852A0 (en) * 1999-03-05 2000-01-31 Compugen Ltd Novel nucleic acid and amino acid sequences
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
US6689866B1 (en) * 1999-03-09 2004-02-10 Curagen Corporation Polynucleotides and proteins encoded thereby
US8410248B2 (en) * 1999-03-12 2013-04-02 Human Genome Sciences Inc. HWBAO62 polypeptides
US8133734B2 (en) * 1999-03-16 2012-03-13 Human Genome Sciences, Inc. Kit comprising an antibody to interleukin 17 receptor-like protein
US6965012B1 (en) * 1999-03-30 2005-11-15 Eli Lilly And Company Flint polypeptide analogs
US6534061B1 (en) * 1999-04-12 2003-03-18 Genentech, Inc. Tumor necrosis factor receptor homologs and nucleic acids encoding the same
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
AU4662400A (en) * 1999-04-26 2000-11-10 Helsinki University Licensing Ltd Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
EP1185559A2 (de) 1999-04-28 2002-03-13 Board Of Regents, The University Of Texas System Zusammensetzungen und verfahren zur krebsbehandlung durch die selektive hemmung von vegf
CA2371702A1 (en) * 1999-04-30 2000-11-09 Toshio Miyata Meg-3 protein
US6475987B1 (en) * 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
JP2003500053A (ja) * 1999-05-20 2003-01-07 サイオス，インコーポレーテッド 血管内皮増殖因子ダイマー
JP2003507006A (ja) 1999-05-20 2003-02-25 サイオス，インコーポレーテッド 血管内皮増殖因子改変体
JP2003500041A (ja) * 1999-05-25 2003-01-07 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Ｍｅｔｈ１およびｍｅｔｈ２ポリヌクレオチドおよびポリペプチド
US20030207793A1 (en) * 1999-05-26 2003-11-06 Conklin Darrell C. Secreted alpha-helical protein - 32
US6781028B1 (en) * 1999-06-14 2004-08-24 Exelixis, Inc. Animal models and methods for analysis of lipid metabolism and screening of pharmaceutical and pesticidal agents that modulate lipid metabolism
US20030153050A1 (en) * 1999-06-28 2003-08-14 Conklin Darrell C. Helical polypeptide zalpha29
US20030096355A1 (en) * 1999-07-09 2003-05-22 Ke Zhang Isolation, identification and characterization of ymkz5, a novel member of the TNF-receptor supergene family
US6951738B2 (en) * 1999-07-16 2005-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptors TR13 and TR14
DK1197496T3 (da) 1999-07-23 2007-10-22 Kenji Kangawa Hidtil ukendte peptider
WO2001010891A2 (en) * 1999-08-05 2001-02-15 Research Corporation Technologies, Inc. Il-16 antagonists
US20030134788A1 (en) * 1999-08-12 2003-07-17 Baker Kevin P. Human tumor necrosis factor receptor TR16
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
NZ523206A (en) * 1999-08-31 2004-12-24 Genentech Inc Antibodies that bind to tumor gene sequences
US20030120037A1 (en) * 1999-09-22 2003-06-26 Ji Ming Wang Utilization of FPRL1 as a functional receptor by serum amyloid a (SAA)
US6998239B1 (en) * 1999-10-12 2006-02-14 Chemocentryx, Inc. Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine
USRE39849E1 (en) 1999-10-12 2007-09-18 Chemocentryx, Inc. Methods for identifying modulators of CCX CKR activity
ATE402953T1 (de) * 1999-10-18 2008-08-15 Lexicon Pharmaceuticals Inc Menschliches chordin und polynukleotiden die dafür kodieren
US7459308B2 (en) * 1999-10-21 2008-12-02 Arbor Vita Corporation Nucleic acid molecule encoding a CLASP-2 transmembrane protein
US6726718B1 (en) 1999-12-13 2004-04-27 St. Jude Medical, Inc. Medical articles prepared for cell adhesion
US7029857B1 (en) * 1999-12-17 2006-04-18 H. Lundbeck A/S Processes for obtaining compounds employing SNORF72 receptors
JP2001211886A (ja) * 2000-02-07 2001-08-07 Japan Science & Technology Corp Ｌ−体及びｄ−体アミノ酸を輸送するナトリウム非依存性小型中性アミノ酸トランスポーター及びその遺伝子
CA2897626C (en) * 2000-02-11 2020-03-24 Biogen Idec Ma Inc. Heterologous polypeptide of the tnf family
WO2001062942A2 (en) 2000-02-25 2001-08-30 Ludwig Institute For Cancer Research MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS
US20030165891A1 (en) * 2000-02-29 2003-09-04 Millennium Pharmaceuticals, Inc. Novel TWIK-6, TWIK-7, IC23927, TWIK-8, IC47611, IC47615, HNMDA-1, TWIK-9 alpha2delta-4, 54414, and 53763 molecules and uses therefor
WO2001065927A1 (en) * 2000-03-03 2001-09-13 University Of Utah Research Foundation Mass1 gene, a target for anticonvulsant drug development
US7514239B2 (en) * 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
US20030119739A1 (en) * 2000-03-29 2003-06-26 Beth Israel Deaconess Medical Center Anti-angiogenic and anti-tumor properties of Vascostatin and other nidogen domains
US7070946B2 (en) * 2000-05-23 2006-07-04 Tanabe Seiyaku Co., Ltd. Bone metabolism related protein and gene thereof
MXPA02011938A (es) * 2000-05-31 2004-09-06 Johnson & Johnson Adn que codifica para un receptor de histamina de mamifero del subtipo h4.
US20030059461A1 (en) * 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
AU8183601A (en) * 2000-06-21 2002-01-02 Merck Patent Gmbh A g-protein coupled receptor
JP2004505619A (ja) * 2000-08-04 2004-02-26 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
AU2001283229A1 (en) * 2000-08-07 2002-02-18 Zymogenetics Inc. Snake venom polypeptide zsnk1
CA2421588C (en) * 2000-09-05 2010-01-26 Amgen Inc. Tnf receptor-like molecules and uses thereof
EP1356045A2 (de) * 2000-10-13 2003-10-29 Nuvelo, Inc. Egf motiv protein, egfl6 materialien und methoden
US6489456B1 (en) * 2000-10-27 2002-12-03 Pe Corporation (Ny) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
GB0028971D0 (en) * 2000-11-28 2001-01-10 Inpharmatica Ltd Novel proteins
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
AU2884102A (en) * 2000-12-07 2002-06-18 Sangamo Biosciences Inc Regulation of angiogenesis with zinc finger proteins
US20040072997A1 (en) * 2000-12-20 2004-04-15 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030180309A1 (en) * 2001-01-08 2003-09-25 Baum Peter R. Human B7 polypeptides
AU2002309473A1 (en) * 2001-01-08 2002-10-08 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US20030114371A1 (en) * 2001-02-07 2003-06-19 Feder John N. Polynucleotide encoding a novel human potassium channel beta-subunit, K+betaM3
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
JP2004521128A (ja) * 2001-02-23 2004-07-15 ワイス Ｂｍｐによるヒト骨髄由来ｃｄ１０５＋細胞の軟骨形成能
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US7741049B2 (en) * 2001-03-15 2010-06-22 Sumitomo Chemical Company, Limited Analysis of agonist-activity and antagonist-activity to cytokinin receptor
US6962971B2 (en) * 2001-03-16 2005-11-08 The Regents Of The University Of California Chemokines and methods for inducing the differentiation of fibroblasts to myofibroblasts
EP1372698A2 (de) * 2001-03-23 2004-01-02 BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH Verwendung von zytokinen der tgf-beta superfamilie zur behandlung und diagnose von hauterkrankungen
WO2002083860A2 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US7795218B2 (en) * 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
CA2444632A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
AU2002256172A1 (en) * 2001-04-13 2002-10-28 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20030176674A1 (en) * 2001-04-13 2003-09-18 Rosen Craig A. Vascular endothelial growth factor 2
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US6878729B2 (en) 2001-05-04 2005-04-12 The Procter & Gamble Company Medicinal uses of dihydropyrazoles
GB0119015D0 (en) * 2001-08-03 2001-09-26 Univ Cardiff A fusion protein
US20030086872A1 (en) * 2001-08-15 2003-05-08 Jean-Philippe Girard SUT-2 and SUT-3 genes, proteins and assays for inhibitors of lymphocyte adhesion
US7265089B2 (en) * 2001-08-21 2007-09-04 Chiron Corporation KGF polypeptide compositions
US7217570B2 (en) * 2001-08-23 2007-05-15 The Wistar Institute Of Anatomy And Biology Organotypic intestinal culture and methods of use thereof
MXPA04001986A (es) * 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
US20050222070A1 (en) * 2002-05-29 2005-10-06 Develogen Aktiengesellschaft Fuer Entwicklungsbiologische Forschung Pancreas-specific proteins
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20040031067A1 (en) * 2001-10-11 2004-02-12 Meenhard Herlyn Regulation of human skin healing
EP1439235A4 (de) * 2001-10-12 2006-01-18 Astellas Pharma Inc Verfahren zum nachweis von zelltod-inhibitoren
WO2003033665A2 (en) * 2001-10-17 2003-04-24 Zymogenetics, Inc. Secreted protein, ztnf9
US7371258B2 (en) * 2001-10-26 2008-05-13 St. Jude Medical, Inc. Valved prosthesis with porous substrate
US6671189B2 (en) * 2001-11-09 2003-12-30 Minebea Co., Ltd. Power converter having primary and secondary side switches
US20030093147A1 (en) * 2001-11-13 2003-05-15 Ogle Matthew F. Medical devices that stimulate growth factor production
US20050137130A1 (en) * 2001-11-14 2005-06-23 Bodmer Mark W. Medical treatment
US20030157525A1 (en) * 2001-11-26 2003-08-21 Mintier Gabriel A. Novel human G-protein coupled receptor, HGPRBMY31, and variants and methods of use thereof
US20030104496A1 (en) * 2001-11-30 2003-06-05 Cytokinetics, Inc. Novel motor protein of P. falciparum and methods for its use
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
AU2003205615B2 (en) * 2002-01-10 2008-09-25 Universiteit Gent A novel splice variant of MyD88 and uses thereof
US20040162237A1 (en) * 2002-01-15 2004-08-19 Fox Niles Wayne Use of lp82 to treat body weight disorders
KR20030062789A (ko) * 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 ｓｉｍ2-ｂｔｍ 및 이것을포함하는 생명공학제품
KR20030062788A (ko) 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 ｍｐｈ1-ｂｔｍ 및 이것을포함하는 생명공학제품
US20050124800A1 (en) * 2002-01-23 2005-06-09 Lindsey Suzanne J. Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells
EP1474515A2 (de) * 2002-02-01 2004-11-10 Bayer HealthCare AG Regulierung eines menschlichen hematopoietin rezeptor ähnlichen proteins
GB0202906D0 (en) 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
US20030180259A1 (en) * 2002-03-12 2003-09-25 Harold Brem Method for treating diabetic ulcers
WO2003080667A2 (en) * 2002-03-22 2003-10-02 Bioxell S.P.A. A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CN1646688A (zh) * 2002-03-28 2005-07-27 遗传学公司 生长调控蛋白质
EP1499729B9 (de) * 2002-04-18 2012-03-14 Yeda Research And Development Co., Ltd. Derivate eines nf-kappab induzierenden enzyms, verfahren zur herstellung der derivate und deren verwendung
CA2483701A1 (en) * 2002-04-24 2003-11-06 Banyu Pharmaceutical Co., Ltd. Constitutively active histamine h3 receptor mutants and uses thereof
US20030055221A1 (en) * 2002-05-07 2003-03-20 Jirong Lu Stability of flint through o-linked glycosylation
EP1382613A1 (de) * 2002-07-16 2004-01-21 Sumitomo Chemical Company, Limited Neues G Protein, kodierende Nukleotidsequenzen und Verwendung des Proteins
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
EA200500232A1 (ru) 2002-07-19 2005-12-29 Бет Изрейэл Диконисс Медикал Сентер Способы диагностики и лечения преэклампсии или эклампсии
GB0219303D0 (en) * 2002-08-19 2002-09-25 Ares Trading Sa Protein
CA2497226A1 (en) * 2002-09-10 2004-03-25 Lorantis Limited Pharmaceutical compositions and medical treatments comprising notch ligand proteins
MXPA05003869A (es) * 2002-10-08 2005-06-22 Ares Trading Sa El uso de citocina capaz de enlazarse a la proteina de union a interleucina-18, y de inhibir la actividad de una segunda citocina.
GB0223984D0 (en) * 2002-10-15 2002-11-20 Novartis Forschungsstiftung Methods for detecting teneurin signalling and related screening methods
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
US7060684B1 (en) 2002-12-16 2006-06-13 Quijano Rodolfo C Device for treating diabetes and methods thereof
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
US20040235747A1 (en) * 2003-01-02 2004-11-25 Ramot At Tel-Aviv University Ltd. Methods of treating and/or preventing autoimmune diseases
WO2004062621A2 (en) * 2003-01-13 2004-07-29 Georgia Tech Research Corporation Anti-inflammatory agents and methods of their use
AU2004210439A1 (en) * 2003-02-05 2004-08-19 Applied Research Systems Ars Holding N.V. Mucin-like polypeptides
US7736646B2 (en) * 2003-03-12 2010-06-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis with apelin compositions
US7084246B2 (en) * 2003-04-17 2006-08-01 Molecular Logix, Inc. Epidermal growth factor agonists
NZ543365A (en) 2003-04-18 2009-02-28 Biogen Idec Inc Polymer-conjugated glycosylated neublastin
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
WO2005110009A2 (en) * 2003-07-22 2005-11-24 Immunex Corporation COMPOSITIONS AND METHODS RELATING TO TSP-30a, b, c AND d
KR100632985B1 (ko) * 2003-07-26 2006-10-11 메덱스젠 주식회사 생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
EP3168304A1 (de) * 2003-08-27 2017-05-17 Ophthotech Corporation Kombinationstherapie zur behandlung neovaskulärer erkrankungen
CA2535021A1 (en) * 2003-09-08 2005-03-17 Applied Research Systems Ars Holding N.V. Use of insp035 to treat fibrotic disease
EP1672062B1 (de) * 2003-09-11 2012-05-09 Hubit Genomix, Inc. Verfahren und kit zum nachweis von sklerose verursachenden proliferativen erkrankungen und/oder heilmittel gegen sklerose verursachende proliferative erkrankungen sowie verfahren und kit zur identifizierung einer bei der vorbeugung und/oder behandlung von sklerose verursachenden proliferativen erkrankungen wirksamen substanz
ZA200603396B (en) * 2003-09-29 2007-11-28 Warren Pharmaceuticals Inc Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US20060104978A1 (en) * 2003-10-24 2006-05-18 Ludwig Institute For Cancer Research Methods and compositions for PDGF-C activation and inhibition
EP2385069A3 (de) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonataler Fc-Rezeptor (FcRn)-bindende Polypeptidvarianten, dimere Fc-Bindungsproteine und damit in Zusammenhang stehende Verfahren
WO2005051994A2 (en) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Ztnf11, a tumor necrosis factor
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
CA2548769A1 (en) * 2003-12-16 2005-06-30 Zymogenetics, Inc. Ztnf 12, a tumor necrosis factor
WO2005063820A2 (en) * 2003-12-30 2005-07-14 Merck Patent Gmbh Il-7 fusion proteins
US20050176073A1 (en) * 2004-02-06 2005-08-11 Chemocentryx, Inc. Cell proliferation associated with CCX CKR expression
AU2005244167A1 (en) * 2004-05-04 2005-11-24 Beth Israel Deaconess Medical Center Methods and compositions for treatment of preeclampsia
EP1612892B1 (de) * 2004-06-30 2008-03-19 Tyco Electronics Nederland B.V. Verbinder für elektronische Bauteile
AU2005273968A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
AU2005272653A1 (en) * 2004-08-13 2006-02-23 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
KR101215697B1 (ko) * 2004-08-19 2012-12-28 바이오겐 아이덱 엠에이 인코포레이티드 뉴블라스틴 변형체
AR050608A1 (es) * 2004-08-19 2006-11-08 Alza Corp Aparato y metodo para administracion transdermica de factores de crecimiento endotelial vascular
KR101241551B1 (ko) * 2004-08-19 2013-03-11 바이오겐 아이덱 엠에이 인코포레이티드 전환 성장 인자 베타 패밀리 단백질의 리폴딩
US20070166281A1 (en) * 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
US20080171033A1 (en) * 2004-08-26 2008-07-17 Chiwen Chang Compositions and methods for treating diseases associated with angiogenesis and inflammation
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
KR101356894B1 (ko) * 2004-09-24 2014-02-06 베스 이스라엘 데코니스 메디칼 센터 임신성 합병증의 진단 및 치료 방법
US20060090646A1 (en) * 2004-11-04 2006-05-04 Questair Technologies Inc. Adsorbent material for selective adsorption of carbon monoxide and unsaturated hydrocarbons
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
MX2007006057A (es) 2004-11-18 2007-12-10 Imclone Systems Inc Anticuerpos contra receptor de factor de crecimiento endotelial vascular-1.
US20080026410A1 (en) * 2004-12-02 2008-01-31 Antonia Vlahou Biomarkers for Bladder Cancer
CA2591142A1 (en) * 2004-12-15 2007-05-10 Beth Israel Deaconess Medical Center, Inc. Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
JP2008526234A (ja) 2005-01-05 2008-07-24 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏ結合分子
EP2314614B1 (de) 2005-02-28 2015-11-25 Sangamo BioSciences, Inc. Anti-angiogene Verfahren und Zusammensetzungen
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
CN101137906A (zh) * 2005-03-23 2008-03-05 惠氏公司 对gdf-8调节剂的免疫应答的检测
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
BRPI0613284A2 (pt) * 2005-06-17 2010-12-28 Genentech Inc métodos de aceleração de cicatrização de ferida
WO2006138646A2 (en) * 2005-06-17 2006-12-28 The Brigham And Women's Hospital, Inc. Protein profile for osteoarthritis
US8329175B2 (en) * 2005-08-26 2012-12-11 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders
US7659250B2 (en) * 2005-12-22 2010-02-09 Centocor, Inc. BMP-7 variant compositions, methods and uses
ATE497973T1 (de) 2005-12-22 2011-02-15 Genentech Inc Rekombinante produktion heparinbindender proteine
US20080064631A1 (en) * 2006-01-13 2008-03-13 Jeffrey Molldrem T-cell receptors for use in diagnosis and therapy of cancers and autoimmune disease
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
EP1993590B1 (de) * 2006-03-01 2013-12-25 Biogen Idec MA Inc. Zusammensetzungen und verfahren zur verabreichung von proteinen der gdnf-liganden-familie
GB0604460D0 (en) * 2006-03-06 2006-04-12 Isis Innovation Treatment
US9878003B2 (en) 2006-03-06 2018-01-30 The University Of Manchester Method of treating bone disorders using TSG-6
US8101564B2 (en) * 2006-05-03 2012-01-24 Trustees Of The University Of Pennsylvania Methods for regulating osteoclast differentiation and bone resorption using LRRc17
EP2548579B1 (de) * 2006-05-17 2015-09-02 The Ludwig Institute for Cancer Research Targeting der Regulierung von Fettsäuretransportern durch VEGF-B zur Modulation menschlicher Krankheiten
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US8901094B2 (en) * 2006-07-04 2014-12-02 Combigene Ab Use of nucleic acid sequences for the treatment of epilepsy
BRPI0713252C1 (pt) 2006-07-14 2021-05-25 Genentech Inc processo para a recuperação de fator de crescimento endotelial vascular (vegf) recombinante reenovelado
AR062271A1 (es) * 2006-08-07 2008-10-29 Genzyme Corp Uso de una cantidad efectiva de al menos un inhibidor de cxcr4, al menos un agonista de cxcr2 y g-csf para movilizar las celulas progenitoras y/o celulas madre
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
US8865169B2 (en) * 2007-02-20 2014-10-21 Tufts University Methods and systems for multi-antibody therapies
KR100984483B1 (ko) * 2007-03-19 2010-10-01 (주)바이오니아 순환적 역전사 방법
EP2136778A2 (de) * 2007-03-20 2009-12-30 Harold Brem Wachstumsfaktorvermittelte kosmezeutika und ihre verwendung zur verbesserung der hautqualität
EP2139447A2 (de) * 2007-03-20 2010-01-06 Harold Brem Gm-csf-kosmezeutikazusammensetzungen und verfahren zu ihrer verwendung
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
TWI445544B (zh) * 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
WO2009126698A2 (en) * 2008-04-09 2009-10-15 Ludwig Institute For Cancer Research Regulation of fatty acid transporters
EP2310507A4 (de) 2008-07-08 2013-03-20 David Gladstone Inst Verfahren und zusammensetzungen zur angiogenesemodulierung
WO2010085606A1 (en) * 2009-01-22 2010-07-29 Case Western Reserve University Protein biomarkers and therapeutic targets for osteoarthritis
EP2414043B1 (de) * 2009-03-30 2016-01-13 Acceleron Pharma Inc. Bmp-alk3-antagonisten und ihre verwendung zur förderung des knochenwachstums
WO2010127304A2 (en) * 2009-05-01 2010-11-04 Illumina, Inc. Sequencing methods
WO2011005298A2 (en) * 2009-06-23 2011-01-13 The Regents Of The University Of California Enhancement of bmp retention
US9409983B2 (en) * 2009-07-23 2016-08-09 The Board Of Trustess Of The University Of Illinois Methods and compositions involving PBEF inhibitors for lung inflammation conditions and diseases
EP2536432B1 (de) * 2010-02-19 2018-08-08 Cornell University Verfahren zur behandlung demyelinisierender autoimmunerkrankungen und anderer autoimmun- oder entzündungserkrankungen
US8853164B2 (en) * 2010-02-26 2014-10-07 Osstemimplant Co., Ltd. Oligopeptide improving differentiation of osteoblasts
US20110218141A1 (en) * 2010-03-03 2011-09-08 Hamrick Mark W Leptin therapy to increase muscle mass and to treat muscle wasting conditions
EP2569253A4 (de) 2010-05-14 2013-10-02 Beth Israel Hospital Extrakorporale vorrichtungen und verfahren zur behandlung von komplikationen während einer schwangerschaft
CA2802994A1 (en) * 2010-06-17 2011-12-22 The United States Of America As Represented By The Secretary, National I Nstitutes Of Health Compositions and methods for treating inflammatory conditions
EP3560962A1 (de) 2010-07-09 2019-10-30 Bioverativ Therapeutics Inc. Verarbeitbare einkettige moleküle und daraus hergestellte polypeptide
US20120171769A1 (en) * 2010-12-30 2012-07-05 Mcgonigle Joseph S Cell attachment coatings and methods
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
US8507446B2 (en) * 2011-08-09 2013-08-13 Mackay Memorial Hospital Use of PEDF-derived polypeptides for treating liver cirrhosis
EP2802606B1 (de) 2012-01-10 2018-04-25 Biogen MA Inc. Verbesserung des transportes von therapeutischen molekülen durch die blut-hirn-schranke
US9920295B2 (en) * 2012-02-21 2018-03-20 The Trustees Of The University Of Pennsylvania Bioreactor for isolation of rare cells and methods of use
EP2830646B1 (de) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von stoffwechselerkrankungen
US9133440B2 (en) * 2012-09-27 2015-09-15 Claresa Levetan Generation of new pancreatic beta cells
AU2014212640B2 (en) 2013-01-30 2017-10-19 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
SG10201913874TA (en) 2013-03-15 2020-03-30 Biogen Ma Inc Factor ix polypeptide formulations
MX2016000364A (es) 2013-07-12 2016-05-09 Ophthotech Corp Metodos para tratar o prevenir afecciones oftalmologicas.
CA2933552A1 (en) * 2013-12-23 2015-07-02 Alk-Abello A/S Peptide combinations and uses thereof in treating dust mite allergy
UA123432C2 (uk) 2014-07-30 2021-04-07 Нджм Біофармасьютікалз, Інк. Димер та спосіб його застосування для лікування метаболічних розладів
AU2015339130C1 (en) 2014-10-31 2021-03-18 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CA2975525A1 (en) 2015-02-04 2016-08-11 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
CN107636159B (zh) 2015-02-04 2022-06-14 百时美施贵宝公司 选择治疗性分子的方法
EP3995581A3 (de) 2015-04-03 2022-10-26 University of Massachusetts Oligonukleotidverbindungen zur behandlung von präeklampsie und anderen angiogenen erkrankungen
AU2017210726B2 (en) 2016-01-31 2023-08-03 University Of Massachusetts Branched oligonucleotides
MY194669A (en) 2016-03-31 2022-12-12 Ngm Biopharmaceuticals Inc Binding Proteins and Methods of use Thereof
WO2018031933A2 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
KR20210093227A (ko) 2018-08-10 2021-07-27 유니버시티 오브 매사추세츠 Snp를 표적화하는 변형된 올리고뉴클레오티드
AU2022299169A1 (en) 2021-06-23 2024-02-08 Beth Israel Deaconess Medical Center, Inc. Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61272063A (ja) * 1985-05-29 1986-12-02 東レ株式会社 マスク
JPH0638860B2 (ja) * 1986-06-30 1994-05-25 日本バイリ−ン株式会社 成形マスク
DE3735787A1 (de) * 1987-09-22 1989-03-30 Stiftung Inst Fuer Werkstoffte Verfahren und vorrichtung zum zerstaeuben mindestens eines strahls eines fluessigen stoffs, vorzugsweise geschmolzenen metalls
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
WO1990011084A1 (en) * 1989-03-24 1990-10-04 The Regents Of The University Of California Endothelial cell growth factor, isolation and expression
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
JPH06339542A (ja) * 1994-04-20 1994-12-13 Asahi Chem Ind Co Ltd 防塵マスク
JPH08107939A (ja) * 1994-10-11 1996-04-30 Takehiko Tatsumi マスク
JP4251677B2 (ja) * 1997-10-13 2009-04-08 大和紡績株式会社 使い捨てマスク
JP3578631B2 (ja) * 1998-06-16 2004-10-20 サンエム・パッケージ株式会社 マスク

Also Published As

Publication number Publication date
EP0484401A1 (de) 1992-05-13
DK0484401T3 (da) 1996-09-30
JP2007068545A (ja) 2007-03-22
WO1991002058A1 (en) 1991-02-21
JPH05501350A (ja) 1993-03-18
ES2094159T3 (es) 1997-01-16
DE69028535D1 (de) 1996-10-17
US5194596A (en) 1993-03-16
CA2063810C (en) 2003-02-04
CA2063810A1 (en) 1991-01-28
AU6079890A (en) 1991-03-11
JPH10309191A (ja) 1998-11-24
JP2004000255A (ja) 2004-01-08
EP0484401B1 (de) 1996-09-11
EP0484401A4 (en) 1992-08-19
ATE142693T1 (de) 1996-09-15
JP3523645B2 (ja) 2004-04-26

Similar Documents

Publication Publication Date Title
DE69028535D1 (de) Herstellung des vaskulären endothelialen zellwachstumsfaktors
DE3752364D1 (de) Osteoinduktive Zusammensetzungen
ATE209251T1 (de) Knochen- und knorpel-bildung hervorrufende proteine
DE693928T1 (de) Aminozucker- und glykosaminoglykanzusammensetzung zur behandlung und reparatus von bindegewebe
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
ES2127757T3 (es) Composiciones bmp-9.
DK0535091T3 (da) Knogleinducerende farmaceutiske formuleringer
ES8600613A1 (es) Procedimiento para el tratamiento de tejidos corporales
DK0429570T3 (da) Osteoinducerende præparater
DE69132918D1 (de) Gewebeabdeckung und wachstumsfaktor enthaltende verbindungen zur förderung beschleunigter wundheilung
DK0691849T3 (da) Osteoblastvækststimulerende præparat indeholdende PDGF og vitamin D
ATE106754T1 (de) Verfahren zur herstellung von rinder-pericard- materialien und ihre verwendung.
ATE253589T1 (de) Bmp-5-derivate
RU93037867A (ru) Способ лечения длительно незаживающих ран и трофических язв кожных покровов
NZ333652A (en) Inhibition of human rotavirus infection using kappa-casein

Legal Events

Date Code Title Description
8364 No opposition during term of opposition